Parallel Advisors LLC Has $870,000 Stake in IQVIA Holdings Inc. $IQV

Key Points

• Parallel Advisors LLC reduced its stake in IQVIA Holdings Inc. by 37.8%, selling 3,354 shares during the second quarter, leaving them with a total of 5,521 shares valued at $870,000.
• Recent changes in institutional ownership include Brighton Jones LLC increasing its position by 244.4% and Voloridge Investment Management LLC boosting its stake by 325.7%, highlighting significant investment interest in the company.
• IQVIA reported a quarterly earnings per share of $2.81, exceeding analyst expectations, with revenues of $4.02 billion, marking a year-over-year increase of 5.3%.

Parallel Advisors LLC lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 37.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,521 shares of the medical research company's stock after selling 3,354 shares during the period. Parallel Advisors LLC's holdings in IQVIA were worth $870,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board increased its holdings in IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock worth $810,069,000 after purchasing an additional 312,807 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after purchasing an additional 798,534 shares in the last quarter. American Century Companies Inc. increased its holdings in IQVIA by 26.8% during the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock worth $253,695,000 after purchasing an additional 304,258 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in IQVIA by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock worth $251,852,000 after purchasing an additional 40,699 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in IQVIA by 13.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock worth $273,766,000 after purchasing an additional 167,057 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent research reports. Barclays increased their price objective on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Redburn Partners set a $214.00 price objective on shares of IQVIA in a research note on Wednesday, September 3rd. Robert W. Baird increased their price objective on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Mizuho increased their price objective on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Finally, Evercore ISI increased their price objective on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $229.64.

IQVIA Trading Down 1.5%

Shares of NYSE:IQV traded down $2.91 during mid-day trading on Friday, reaching $187.29. 2,104,117 shares of the company's stock were exchanged, compared to its average volume of 1,124,593. The firm has a market capitalization of $31.84 billion, a price-to-earnings ratio of 27.10, a PEG ratio of 2.06 and a beta of 1.32. The business's fifty day moving average price is $184.79 and its 200-day moving average price is $167.31. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $245.20.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA's revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.